Comparative platelet activation profile between pooled granulocyte concentrates (PGC) versus apheresis (APC) and buffy coat (BC-PC) method.

BACKGROUND

Granulocyte transfusion remains a therapeutic option for patients with severe neutropenia or granulocyte dysfunction, though its clinical benefit is still debated. Traditional pooled granulocyte concentrates (PGC) are produced by donor stimulation and apheresis, procedures that are costly and ethically restrictive. To overcome these limitations, PGC derived from buffy coat layers (BC) have emerged as a simpler and safer alternative, yet little is known about their platelet composition and activation profile.

STUDY DESIGN /

METHODS

Whole blood donations (n = 256) were processed into BC, pooled (20 BC per batch), and reconstituted to form PGC20 units. Hematologic parameters and platelet activation markers (CD41, CD62P, CD63) were analyzed by automated counting and flow cytometry and compared with standard apheresis (APC) and buffy coat-derived platelet concentrates (BC-PC).

RESULTS

PGC show a high platelet concentration comparable to BC-PC, with an increased mean platelet volume. The elevated expression of CD62P and CD63 confirms marked platelet activation, while the slight decrease in CD41 suggests membrane alteration during processing, indicating a mixed platelet-granulocyte product with immunomodulatory potential that requires optimization for safe transfusional use.

CONCLUSIONS

PGC derived from buffy coat pools combines high granulocyte yield with an activated platelet population. This bioactive platelet component may enhance immune interactions but warrants further optimization to ensure transfusion safety and product standardization.